Drug major Lupin, which has been reeling under intense pricing pressure for its key products in the US, is trying to chart a growth path. Its recently announced acquisition in the US is a step in that direction. The buy will give the company access to the brand Solosec in the women’s health care segment, besides existing products such as Methergin and a few oral contraceptives (many more products are lined up for approval). The acquisition of a brand has its own benefits such as better margins and is also a long-term growth driver compared to generics that tend to face ...
TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
LOGIN
Not a member yet ? Resister Now
Connect using any below
WHAT YOU GET
On Business Standard Digital
On
Digital
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital
Already registered ?